Table 3.

PFS and OS.

Survival		DTC	DTC + CIK	Total
Total patients (No.)		40	12	52
PFS, months	Median	4	6	4
	95% CI	3.37–4.63	2.61–9.40	3.33–4.67
OS, months	Median	13	16	14
	95% CI	8.78–17.22	10.34–21.66	11.53–16.47
Patients with measurable disease (No.)		37	9	46
PFS, months	Median	4	5	4
	95% CI	3.43–4.57	2.08–7.92	3.39–4.61
OS, months	Median	12	16	14
	95% CI	8.40–15.60	13.08–18.92	10.04–17.96
Total platinum-resistant/refractory patients (No.)		19	8	27
PFS, months	Median	4	8	6
	95% CI	2.64–5.36	5.23–10.77	5.03–6.97
OS, months	Median	12	19	15
	95% CI	8.21–15.79	13.46–24.54	10.35–19.65
Total platinum-sensitive patients (No.)		21	4	25
PFS, months	Median	3	2	3
	95% CI	1.80–4.20	–	3.38–4.62
OS, months	Median	14	8	14
	95% CI	8.86–19.14	0–20.74	8.25–19.75
Disease measurable platinum-resistant/refractory (No.)		17	5	22
PFS, months	Median	4	8	5
	95% CI	3.25–4.75	4.78–11.22	3.52–6.50
OS, months	Median	10	19	14
	95% CI	6.26–13.74	12.56–25.44	9.79–18.22
Disease measurable platinum-sensitive (No.)		20	4	24
PFS, months	Median	3	2	3
	95% CI	1.64–4.36	—	1.02–4.99
OS, months	Median	14	8	14
	95% CI	9.11–18.89	0–20.74	8.46–19.54

CI, confidence interval.